August 5, 2013 — AstraZeneca announced results from a new sub-analysis of the PLATO study that evaluated the incidence of stent thrombosis in patients with acute coronary syndrome (ACS).

Thubrikar Aortic Valve’s Optimum TAV, transcatheter aortic valve implantation (TAVI) system, has surpassed 200 million cycles in an ongoing durability test — which simulates over five years in humans and meets the requirement set by the International Organization for Standardization (ISO) — in a third party GLP study.

Abiomed Inc. reported that physicians have implanted more than 15,000 Impella pumps in U.S. patients requiring hemodynamic support. The 15,000th Impella procedure took place at Mercy General Hospital in Sacramento, Calif., with an Impella pump that provided prophylactic circulatory support.

The U.S. Food and Drug Administration (FDA) recently granted market clearance for a hand lotion designed to offer radiation protection from X-rays. Physicians such as interventional cardiologists who work with live angiographic fluoroscopic X-ray systems often have their hands in the radiation field during imaging. The cream, developed by radiation protection product company BloXR Corp., is applied prior to donning gloves, or over a glove with another glove on top, to serve as a lightweight radiation shield

Abbott announced results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay. The study, conducted by researchers at Brigham and Women's Hospital, demonstrated that Abbott's hsTnI test (currently for research-use only in the United States) may help doctors predict which patients presenting with symptoms of a heart attack, such as severe chest pain, are at a higher risk for having a heart attack 30 days later.

Mercator MedSystems has been issued U.S. Patent 8,465,752, which protects the company’s sole U.S. rights to deliver drugs or other nerve modifying agents to tissue surrounding arteries for renal denervation (RDN). The system also can be used for carotid body modulation (CBM) procedures. 

InspireMD Inc. said the first patient has been enrolled in the Master II IDE clinical trial to evaluate the safety and effectiveness of the MGuard Prime Embolic Protection Stent (EPS) in patients suffering from ST elevation myocardial infarction (STEMI).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now